Contribute Try STAT+ Today

A federal watchdog is being asked to investigate the Food and Drug Administration for an “inappropriate collaboration” with Biogen (BIIB) in readying an application for regulatory approval to market its controversial Alzheimer’s treatment.

In a scathing letter to the Office of Inspector General at the Department of Health and Human Services, the Public Citizen advocacy group accused the FDA of “unbridled enthusiasm” for the medicine and for pursuing “unprecedented” cooperation with the biotech company, which has “dangerously compromised the independence and objectivity” of FDA senior staff and clinical reviewers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.